Hoechst Aktiengesellschaft

Celltech Limited

Heinz Hanel

Wolfgang Raether

Burkhard Sachse

Walter Dittmar

Joachim Wink

Peter Braun

Peter Eckes

Jurgen Logemann

Jozef Schell

Rolf Hilgenfeld

Norbert Ulbrich

Ulrich Gebert

Wolfgang Schaper

Dieter Bernd Reuschling

Alwin K Reng

Elmar Schrinner

Klaus-Dieter Kampe

Gerhard Lohaus

Hiristo Anagnostopulos

Mark William Bodmer

Michael Limbert

Waltraud Simsch

Heinz Ehrhardt

Bengt-Thomas Grobel

Ernst Blume

Gerald Anthony Higgs

Klaus D Kampe

A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.

Use of antibodies to TNF or fragments derived thereof and xanthine

The polypeptide with the sequence (SEQ ID NO:1) Ala-Thr-Tyr-Asn-Gly-Lys-Cys-Tyr-Lys-Lys-Asp-Asn-Ile-Cys-Lys-Tyr-Lys-Ala-Gln -Ser-Gly-Lys-Thr-Ala-Ile-Cys-Lys-Cys-Tyr-Val-Lys-Lys-Cys-Pro-Arg-Asp-Gly-Al a-Lys-Cys-Glu-Phe-Asp-Ser-Tyr-Lys-Gly-Lys-Cys-Tyr-Cys can be produced by the fermentation of Aspergillus giganteus and used as an antifungal agent. Expression of this polypeptide gene in plants strongly inhibits the growth of phytopathogenic fungi on the plant.

Antifungal polypeptide and process for its production

The polypeptide with the sequence (SEQ ID NO: 1)

The invention relates to cosmetic preparations which have a content of compounds of the general formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 are identical or different and are hydrogen or alkyl with 1 to 4 carbon atoms, where R.sup.1 and R.sup.3 are preferably hydrogen and R.sup.2 is preferably methyl,

Antidandruff agents and cosmetic preparations

Pharmaceuticals which contain a substance releasing tumor necrosis factor (TNF) are better tolerated and can be given in higher doses when they contain a TNF inhibitor, especially a xanthine derivative.

Pharmaceutical containing TNF inhibitor

Compounds I ##STR1## where A equals t-butyl or a large number of (substituted) aromatics; Y equals azolyl; or Y equals --X--R.sup.1 where X=oxygen or sulfur and R.sup.1 equals (cyclo)alkyl or (heterocyclic) aryl; or Y equals ##STR2## where R.sup.2 equals (cyclo)alkyl, acetyl or aryl; or Y equals --NR.sup.3 R.sup.4 where R.sup.3 /R.sup.4 is alkyl; or Y equals several nitrogen-containing heterocyclic rings; Z equals OH, alkylcarbonyloxy, hal, alkoxy or benzyloxy; and the salts thereof are effective antimycotics or fungicides. They are obtained by reaction of II ##STR3## with (CH.sub.3).sub.2 ##STR4## and further reaction of the compound IV ##STR5## obtained from this with a nucleophile YM (M=hydrogen or a metal equivalent). The compounds I (where Z=OH) resulting from this can be acylated or alkylated, or converted into I where Z=hal.

1-[1-aryl-1-hydroxy-2-azolyl-ethyl]-1-aryl-cyclopropane derivatives, and

Compounds of the formula I ##STR1## in which A equals CH or N, Ar equals phenyl, naphthyl or thienyl, R.sup.1 equals alkyl or halogen, and Y is a number of nitrogen-containing heterocyclic rings, have an excellent antimycotic action. The compounds IIIa ##STR2## are valuable intermediates for the preparation thereof.

2-Azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, agents

Compounds I ##STR1## where A equals CH or N; Ar equals naphthyl, thienyl or phenyl; R.sup.1 equals alkyl, F or Cl; g equals zero, 1 or 2; and Y equals various heterocyclic bases, and the acid-addition salts thereof, are described. Several preparation processes are described. The compounds IIIa ##STR2## where R.sup.1, g and Y are as specified in the case of the formula I, serve as intermediates for the preparation of these compounds. Processes are also specified for the preparation of IIIa. I represent valuable antimycotics.

New 1-hydroxy-2-pyridones of the general formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3, which are identical or different, denote hydrogen or lower alkyl having 1-4 carbon atoms, R.sup.1 and R.sup.3 preferably being hydrogen, and R.sup.2 preferably being methyl,

1-hydroxy-2-pyridones, a process for their preparation, and medicaments

Growing community of inventors

Oberursel, Germany

Heinz Hanel